Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
How has the pulmonary embolism market size evolved in recent years?
The pulmonary embolism market has grown rapidly and is projected to expand from $2.03 billion in 2024 to $2.27 billion in 2025 at a CAGR of 11.9%. Factors that have driven historical growth include the development of anticoagulant therapies, ongoing research and clinical trials, greater awareness of pulmonary embolism, and increased focus on venous thromboembolism (VTE) prophylaxis.
What are the predictions for the pulmonary embolism market size in the coming years?
The pulmonary embolism market is forecasted for rapid expansion, hitting $3.63 billion in 2029 at a CAGR of 12.5%. Growth will be supported by targeted therapies, telemedicine, remote monitoring, and global health initiatives. Trends include AI-driven diagnosis, novel anticoagulants, response teams, and patient-centered care.
Get your pulmonary embolism market report here!
https://www.thebusinessresearchcompany.com/report/pulmonary-embolism-global-market-report
What key factors are fueling the growth of the pulmonary embolism market?
The expected surge in the pulmonary embolism market can be attributed to the rising incidences of blood clots. A thrombus or a blood clot is a semi-solid or gel-like lump that forms inside a blood vessel. The occurrence of blood clots escalates the possibility of pulmonary embolism by hindering the flow of blood to the lungs. This blockage caused by the clot normally happens in the deep veins of the legs and heightens the risk of pulmonary embolism. As an example, Gavi, the Vaccine Alliance, an international group committed to enhancing access to new and lesser-used vaccines for children, featured an article in April 2022 revealing that post a 30-day exposure to COVID-19, the odds for severe lung clots rose 33 times, with a fivefold increase in the risk of deep vein thrombosis. Hence, the growing incidence of blood clots is fuelling the expansion of the pulmonary embolism market. The growth of the pulmonary embolism market is also expected to be driven by the increasing prevalence of cancer. Cancer is a collection of diseases that cause cells in the body to multiply abnormally and uncontrollably. The rise in the number of cancer cases elevates the risk of patients developing blood clots such as pulmonary embolism. This, in turn, increases the necessity for diagnostic procedures and treatments, including specific medications. For instance, the number of cancer cases reported by the American Cancer Society, a non-profit cancer advocacy organization based in the USA, rose to 2,001,140 in January 2024, marking a 2.19% increase from 1,958,310 cases in 2023. Therefore, the escalating prevalence of cancer is fuelling the development of the pulmonary embolism market.
How is the global pulmonary embolism market divided into key segments?
The pulmonary embolism market covered in this report is segmented –
1) By Treatment: Medications, Mechanical Devices, Other Treatments
2) By Diagnosis: Chest X-Ray, Electrocardiogram (ECG), Magnetic Resonance Imaging (MRI), Computed Tomography Scan, Pulmonary Angiography, Venography, Venous Ultrasound, D-Dimer Test, Other Diagnosis
3) By Symptoms: Shortness Of Breath, Chest Pain, Cough, Irregular Heartbeat, Dizziness, Fever, Cyanosis, Other Symptoms
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels
5) By End-User: Hospitals, Specialty Clinics, Homecare, Other End-Users
Subsegments:
1) By Medications: Anticoagulants, Thrombolytics
2) By Mechanical Devices: Inferior Vena Cava (IVC) Filters, Catheter-Assisted Thrombectomy
3) By Other Treatments: Surgical Embolectomy, Supportive Care
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13026&type=smp
Who are the key firms paving the way for growth in the pulmonary embolism market?
Major companies operating in the pulmonary embolism market are Pfizer Inc., Johnson and Johnson Private Limited, F. Hoffmann-La Roche Ltd., Merck And Co.Inc., Novartis AG, Bayer AG, Sanofi S.A., Bristol Myers Squibb Company, GSK PLC, Abbott Laboratories, AstraZeneca PLC, Medtronic PLC, Eli Lilly and Company, Gilead Sciences Inc., Baxter International Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Mylan N.V., Daiichi Sankyo Co. Ltd., Boehringer Ingelheim International GmbH, Mitsubishi Tanabe Pharma Corporation, Genentech Inc., Hikma Pharmaceuticals PLC, Aspen Pharmacare Holdings Limited, Nippon Shinyaku Co. Ltd., Penumbra Inc., Fresenius Kabi AG, Inari Medical Inc., AngioDynamics Inc., Otsuka Pharmaceutical Co. Ltd.
Which trends are expected to transform the pulmonary embolism market?
Leading firms within the pulmonary embolism sector are investing in the creation of novel products such as the Triever16 Curve catheter and the RevCore thrombectomy catheter as a way of securing a competitive edge. For example, Inari Medical Inc., located in the US, unveiled the Triever16 Curve catheter along with the RevCore thrombectomy catheter in June 2023. The new Triever16 Curve catheter is specifically created for peripheral thrombectomy and pulmonary embolism operations. This catheter offers excellent trackability and includes a pre-shaped curve for pinpointed aspiration. Its ingenuity lies in its design that facilitates easy access to larger and more potent 20F or 24F catheters. Meanwhile, the RevCore thrombectomy catheter is engineered to manage venous in-stent thrombosis. It is a mechanical thrombectomy tool that utilizes a nitinol basket for capturing and eliminating blood clots. These catheters also serve to enhance the safety and efficiency of pulmonary embolism processes.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13026
What regions are contributing significantly to the growth of the pulmonary embolism market?
North America was the largest region in the pulmonary embolism market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in pulmonary embolism market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Browse Through More Similar Reports By The Business Research Company:
Cardiac Marker Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/cardiac-marker-global-market-report
Cardiac Assist Devices And Equipment Global Market Report 2024
Cardiac Pacemakers Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/cardiac-pacemakers-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
